153 related articles for article (PubMed ID: 7762761)
21. Role of acetylcholine receptor antibody complexes in muscle in experimental autoimmune myasthenia gravis.
Verschuuren JJ; Graus YM; Theunissen RO; Yamamoto T; Vincent A; van Breda Vriesman PJ; De Baets MH
J Neuroimmunol; 1992 Feb; 36(2-3):117-25. PubMed ID: 1732277
[TBL] [Abstract][Full Text] [Related]
22. The severity of myasthenia gravis correlates with the serum concentration of titin and ryanodine receptor antibodies.
Romi F; Skeie GO; Aarli JA; Gilhus NE
Arch Neurol; 2000 Nov; 57(11):1596-600. PubMed ID: 11074791
[TBL] [Abstract][Full Text] [Related]
23. [Acetylcholine receptor antibodies in patients with myasthenia].
Neretin VIa; Kotov SV; Gekht BM; Agafonov BV; Lokhmiuller G; Sidorova OP; Sepp EK; Shcherbakova NI; Kalinenkova SG
Zh Nevrol Psikhiatr Im S S Korsakova; 2002; 102(3):51-3. PubMed ID: 11957349
[TBL] [Abstract][Full Text] [Related]
24. The high frequency and clinical feature of seronegative myasthenia gravis in Southern China.
Feng HY; Wang HY; Liu WB; He XT; Huang X; Luo CM; Li Y
Neurol Sci; 2013 Jun; 34(6):919-24. PubMed ID: 22829131
[TBL] [Abstract][Full Text] [Related]
25. [Value of acetylcholine receptor antibodies in myasthenia gravis].
Zeitlhofer J; Maida EM; Mamoli B; Mayr N
Wien Med Wochenschr; 1986 Jul; 136(13):329-32. PubMed ID: 3765651
[TBL] [Abstract][Full Text] [Related]
26. Acetylcholine receptors loss and postsynaptic damage in MuSK antibody-positive myasthenia gravis.
Shiraishi H; Motomura M; Yoshimura T; Fukudome T; Fukuda T; Nakao Y; Tsujihata M; Vincent A; Eguchi K
Ann Neurol; 2005 Feb; 57(2):289-93. PubMed ID: 15668981
[TBL] [Abstract][Full Text] [Related]
27. Rate of change in acetylcholine receptor antibody levels predicts myasthenia gravis outcome.
Kojima Y; Uzawa A; Ozawa Y; Yasuda M; Onishi Y; Akamine H; Kawaguchi N; Himuro K; Noto YI; Mizuno T; Kuwabara S
J Neurol Neurosurg Psychiatry; 2021 Sep; 92(9):963-968. PubMed ID: 33766920
[TBL] [Abstract][Full Text] [Related]
28. New antigen for antibody detection in myasthenia gravis.
Gotti C; Mantegazza R; Clementi F
Neurology; 1984 Mar; 34(3):374-7. PubMed ID: 6538281
[TBL] [Abstract][Full Text] [Related]
29. Relationship between anti-acetylcholine receptor antibody titres and severity of myasthenia gravis.
Aurangzeb S; Tariq M; Irshad M; Badshah M; Khan RS
J Pak Med Assoc; 2009 May; 59(5):289-92. PubMed ID: 19438131
[TBL] [Abstract][Full Text] [Related]
30. Anti-alkaline phosphatase antibody positive myasthenia gravis.
Konishi T; Ohta K; Shigemoto K; Ohta M
J Neurol Sci; 2007 Dec; 263(1-2):89-93. PubMed ID: 17628604
[TBL] [Abstract][Full Text] [Related]
31. Patient-specific anti=acetylcholine receptor antibody patterns in myasthenia gravis.
Savage-Marengo T; Harrison R; Lunt GG; Behan PO
J Neurol Neurosurg Psychiatry; 1980 Apr; 43(4):316-20. PubMed ID: 7373331
[TBL] [Abstract][Full Text] [Related]
32. Modified and improved anti-acetylcholine receptor (AchR) antibody assay: comparison of analytical and clinical performance with conventional anti-AChR antibody assay.
Ferrero B; Aimo G; Pagni R; Bergamasco B; Bongioanni MR; Bergamini L; Durelli L
Clin Chem; 1997 May; 43(5):824-31. PubMed ID: 9166237
[TBL] [Abstract][Full Text] [Related]
33. Specificities of antibody to acetylcholine receptor in rabbits with experimental myasthenia gravis.
Ueno S; Kang J; Takeuchi H; Takahashi M; Tarui S
Clin Exp Immunol; 1980 Jul; 41(1):13-8. PubMed ID: 6777100
[TBL] [Abstract][Full Text] [Related]
34. Acetylcholine receptor antibody in myasthenia gravis: predominance of IgG subclasses 1 and 3.
Rødgaard A; Nielsen FC; Djurup R; Somnier F; Gammeltoft S
Clin Exp Immunol; 1987 Jan; 67(1):82-8. PubMed ID: 3621677
[TBL] [Abstract][Full Text] [Related]
35. TE671 cell-based ELISA for anti-acetylcholine receptor antibody determination in myasthenia gravis.
Franciotta D; Martino G; Brambilla E; Zardini E; Locatelli V; Bergami A; Tinelli C; Desina G; Cosi V
Clin Chem; 1999 Mar; 45(3):400-5. PubMed ID: 10053042
[TBL] [Abstract][Full Text] [Related]
36. Enzyme-linked immunosorbent assay for antibody against the nicotinic acetylcholine receptor in human myasthenia gravis.
Kawanami S; Tsuji R; Oda K
Ann Neurol; 1984 Feb; 15(2):195-200. PubMed ID: 6367620
[TBL] [Abstract][Full Text] [Related]
37. Myasthenia gravis: comparative autoantibody assays using human muscle, TE671, and glucocorticoid-treated TE671 cells as sources of antigen.
Kennel PF; Vilquin JT; Braun S; Fonteneau P; Warter JM; Poindron P
Clin Immunol Immunopathol; 1995 Mar; 74(3):293-6. PubMed ID: 7859420
[TBL] [Abstract][Full Text] [Related]
38. Acetylcholine receptor antibody characteristics in myasthenia gravis. III. Patients with low anti-AChR antibody levels.
Vincent A; Newsom-Davis J
Clin Exp Immunol; 1985 Jun; 60(3):631-6. PubMed ID: 2410169
[TBL] [Abstract][Full Text] [Related]
39. Prevention of experimental autoimmune myasthenia gravis by manipulation of the immune network with a complementary peptide for the acetylcholine receptor.
Araga S; LeBoeuf RD; Blalock JE
Proc Natl Acad Sci U S A; 1993 Sep; 90(18):8747-51. PubMed ID: 8378359
[TBL] [Abstract][Full Text] [Related]
40. Anti-acetylcholine receptor (AChR) antibodies measurement in myasthenia gravis: the use of cell line TE671 as a source of AChR antigen.
Somnier FE
J Neuroimmunol; 1994 Apr; 51(1):63-8. PubMed ID: 8157737
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
